ERBB2 and neoplasm: Similarly, the standard HER2-CD3-Fc structure has been delivered as an mRNA–LNP, demonstrating high binding affinity and the ability to induce potent, specific T-cell cytotoxicity against HER2-positive tumor cells in vitro and in vivo (282).